Patents
Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
Patent Number: 7,241,812It is known that Sphingosine-1-phosphate mediates migration of mesenchymal stem cells. However, there are numerous receptors by which the effects of sphingosine-1-phosphate are mediated. While the sphingosine-1-phosphate receptor 1 is associated with migration, other activation of other receptors (such as sphingosine-1-phosphate...
Inventors: Saha; Ashis K. (Stow, MA), Kavarana; Malcolm J. (Burlington, MA), Evindar; Ghotas (Waltham, MA), Satz; Alexander L. (Needham, MA), Morgan; Barry (Franklin, MA)
Assignee: Praecis Pharmaceuticals, Inc. (Waltham, MA)
Date of First Priority Issue: Friday August 13th, 2004
Polypeptides that induce cell proliferation or induce fetal hemoglobin
Patent Number: 7,241,862This patent covers several amino acid and nucleotide sequences which are useful for modificatin of cellular differentiation and expansion. The claims refer to several sequence IDs, whereas the specification describes what appears to be numerous disjointed compositions of matter, uses, and formulations. For example, the patent specification talks about cadherins, then IL-17, then semaphorins...
Inventors: Eaton; Dan L. (San Rafael, CA), Goddard; Audrey (San Francisco, CA), Godowski; Paul J. (Hillsborough, CA), Gurney; Austin L. (Belmont, CA), Pan; James (Belmont, CA), Watanabe; Colin K. (Moraga, CA), Wood; William I. (Hillsborough, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Tuesday April 27th, 1999
Assessing the condition of a joint and devising treatment
Patent Number: 7,239,908In stem cell therapy it is not only important to have the right types of stem cells, but it is just as important to know the proper indication and stage of the progression of the indication when intervention is most likely to yeild benefit. This is what the current patent is covering in the area of joint degeneration. The patent covers very interesting methodologies for convering MRI and other...
Inventors: Alexander; Eugene J. (Palo Alto, CA), Andriacchi; Thomas P. (Los Altos Hills, CA), Lang; Philipp (Redwood City, CA), Steines; Daniel (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Wednesday December 16th, 1998
1 Comment
1 Comment
Cationic liposome delivery of taxanes to angiogenic blood vessels
Patent Number: 7,238,369Tumors are highly dependent on angiogenesis. The stem cell compartment is believed to supply circulating angioblasts which leave the bone marrow and home into tumors to support formation of new blood vessels. This patent covers a unique method of specifically targeting chemotherapeutic taxanes to areas of angioblast mediated angiogenesis through the use of cationic lipids. The patent is...
Inventors: McDonald; Donald M. (San Francisco, CA), McLean; John W. (Redwood City, CA), Thurston; O. Gavin (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday March 12th, 1997
Methods and compositions for diagnosing and monitoring transplant rejection
Patent Number: 7,235,358As science progresses to the point of inducing specific differentiation of cellular products from embryonic stem cells, the issue of allogeneic rejection will have to be dealt with. This specific patent provides various inflammatory markers that are useful for knowing when a rejection episode will occur. By identifying when a transplanted cellular product starts undergoing rejection, it is...
Inventors: Wohlgemuth; Jay (Palo Alto, CA), Fry; Kirk (Palo Alto, CA), Woodward; Robert (Pleasanton, CA), Ly; Ngoc (Albany, CA), Prentice; James (San Francisco, TX)
Assignee: Expression Diagnostics, Inc. (South San Francisco, CA)
Date of First Priority Issue: Friday June 8th, 2001
Brain cell or nerve cell-protecting agents comprising medicinal ginseng
Patent Number: 7,235,267Numerous people believe that natural remedies are not patentable. This is not correct. In this specific patent, the use of ginsenoside Rb1 for acceleration of post CNS-infarct healing is covered. While numerous ginseng components have been known to have neuroprotective activities, this patent overcomes obviousness challenges by claiming only specific chemical structures and dosing...
Inventors: Sakanaka; Masahiro (Ehime, JP), Maeda; Nobuji (Ehime, JP), Tanaka; Junya (Ehime, JP), Nakata; Kimihiko (Ehime, JP)
Assignee: Japan Science and Technology Corporation (Saitama, JP)
Date of First Priority Issue: Monday August 30th, 1999
Cloning ungulates from a quiescent donor cell
Patent Number: 7,232,938This is one of the original cloning patents from the inventor of Dolly the sheep :) It covers a method of cloning an ungulate comprising: (i) providing a quiescent ungulate cell as a diploid donor cell; (ii) fusing the diploid donor cell to an enucleated oocyte recipient of the same species as the donor cell, thereby obtaining a reconstituted cell; (iii) activating the oocyte...
Inventors: Campbell; Keith Henry Stockman (Midlothian, GB), Wilmut; Ian (Midlothian, GB)
Assignee: Roslin Institute (Midlothian, GB)
Date of First Priority Issue: Thursday August 31st, 1995
Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
Patent Number: 7,232,798This invention relates to the discovery of the functions of cyclic Propyl Glycine as a novel antagonist that either blocks the AMPA and/or the NMDA receptors. Since agonism of these receptors is associated with excitotoxic neuronal death, the invention covers the use of cyclic propyl glycine as a neuroprotectant in a variety of settings including stroke and neurodegenerative diseases. The...
Inventors: Tran; Loi H. (Elk Grove, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday November 13th, 2001
Process for ex vivo formation of mammalian bone and uses thereof
Patent Number: 7,229,826This patent covers a method of identifying genes associated with generation of bone tissue. The one issued claim covers the growth of a bone progenitor cell in media containing one or more members of the TGF family, and then assessing gene expression modification as the bone progenitor cells are differentiating into bone.
Inventors: Kale; Sujata (Boston, MA), Long; Michael W. (Northville, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Tuesday December 28th, 1999
Method for differentiating mesenchymal stem cells into neural cells
Patent Number: 7,229,827Mesenchymal stem cells are currently in Phase III of clinical trials by companies such as Osiris. Additionally, numerous academic institutions are conducting clinical trials for mesenchymal stem cells. The current patent covers the differentiation of mesenchymal stem cells into neurons by culture with FGF-2, HGF, and EGF. This patent...
Inventors: Kim; Hyun-Soo (Suwon, KR), Yoon; Hee-Hoon (Incheon, KR)
Assignee: FCB-Pharmicell Co., Ltd. (KR); LifeCord International Co., Ltd. (KR)
Date of First Priority Issue: Thursday April 19th, 2001